drugset / Trial / NCT03542799
EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer
Phase 1
Unknown
20 enrolled
Shenzhen Second People's Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR -IL12 -CART) cells in metastatic patients with colorectal cancer.
Timeline
- Start
- 2018-05-22
- Primary completion
- 2020-05-23
- Completion
- 2021-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EGFR IL12 CART | Cell therapy | — | — |